AZBio uses StateNet from Lexis Nexis to stay up to date on what is happening on Capitol Hill and across the 50 states. To get the latest news, delivered to your email mailbox, get your complimentary subscription at StateNet.com or read the copy on-line here.Continue reading
as sent to members of the Arizona Congressional Delegation
August 9, 2011
Changes to Medicare Part D – Please Don’t “Fix” a System That Is Working
We have a lot of things that need fixing at the moment as the financial burden our country bears comes under further review and adjustments. Many of our systems are broken, but some are working. Medicare Part D is one system that works.Continue reading
AZBIO Washington Watch
Several minority organizations and disease advocacy groups are starting a website to track concerns about and opposition to the Independent Payment Advisory Board.Continue reading
WASHINGTON, D.C. (Wednesday, June 29, 2011) – The Biotechnology Industry Organization (BIO) released today a summary of legislative proposals to reform the investment and regulatory environment for biotech innovation. These proposals are designed to unleash the innovation required to cure disease and make the U.S. healthcare system more affordable, efficient, and of higher quality, as well as to foster the development of breakthrough technologies to provide alternative energy sources, combat hunger and protect against bio-terrorism. The policy proposals, released at a press briefing at the 2011 BIO International Convention held here this week, will serve as the organization’s targeted advocacy plan in these two areas.
There has been a lot of talk about budgets and debt ceilings in Washington this week. The negotiations – now taking place between the President and Congressional leaders are fluid, closely held, and difficult to predict. It does not take a PhD to know that Medicare and Medicaid cuts are on the table.
Press Release from BIO: The Leahy-Smith America Invents Act will benefit all sectors of U.S. economy
Washington, D.C. (June 23, 2011) – Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following statement on the passage of The Leahy-Smith America Invents Act, H.R. 1249, by the House of Representatives:
“Small biotechnology companies rely heavily on their patents to attract investment to fund the lengthy and expensive research and development process necessary to bring breakthrough medical therapies and other products to patients and consumers. Strong intellectual property protection is critical for these companies.
“The Leahy-Smith America Invents Act will bring our patent system into the 21st century. The improvements made by the bill will benefit all sectors of the national economy by enhancing patent quality and the efficiency, objectivity, predictability and transparency of the U.S. patent system.
Here’s and update on SBIR and STTR from our friends at BIO in DC.
“Last week the cloture vote to move the SBIR bill toward final passage in the Senate failed and unfortunately the Senate is currently at an impasse.